Lifitegrast ophthalmic solution

From WikiMD's Food, Medicine & Wellness Encyclopedia

(Redirected from Xiidra)

What is Lifitegrast ophthalmic solution?[edit | edit source]

lifitegrast ophthalmic solution is a lymphocyte function-associated antigen-1 (LFA-1) antagonist supplied as a sterile, clear, colorless to slightly brownish-yellow colored, isotonic solution of lifitegrast with a pH of 7.0-8.0, and an osmolality range of 200-330 mOsmol/kg. The chemical name for lifitegrast is (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid. The molecular formula of lifitegrast is C29H24Cl2N2O7S and its molecular weight is 615.5 g/mol.

What are the uses of this medicine?[edit | edit source]

It is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

How does this medicine work?[edit | edit source]

Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in DED is not known.

Who Should Not Use this medicine?[edit | edit source]

It is contraindicated in patients with known hypersensitivity to lifitegrast .

Is this medicine FDA approved?[edit | edit source]

It is approved by US FDA on Jul 12, 2016.

What are the brand names and dosage forms of this medicine?[edit | edit source]

  • Brand name: Xiidra; NDC codes: 0078-0911-05, 0078-0911-12, 0078-0911-94, 0078-0911-95.
  • Ophthalmic solution containing lifitegrast 50 mg/mL (5%).

How should this medicine be used?[edit | edit source]

Instill one drop of Xiidra twice daily (approximately 12 hours apart) into each eye using a single-use container. Discard the single-use container immediately after using in each eye.

What special precautions should I follow?[edit | edit source]

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

What side effects can this medication cause?[edit | edit source]

  • Hypersensitivity

What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Can this medicine be used in pregnancy?[edit | edit source]

There are no available data on Xiidra use in pregnant women to inform any drug-associated risks.

Can this medicine be used in children?[edit | edit source]

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

What should I know about storage and disposal of this medication?[edit | edit source]

Store at 20°C to 25°C (68°F to 77°F). Store single-use containers in the original foil pouch.

Lifitegrast ophthalmic solution Resources
Doctor showing form.jpg

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Bonnu, Prab R. Tumpati, MD